Phoenix Financial Ltd. Has $4.61 Million Stock Holdings in Medtronic PLC $MDT

Phoenix Financial Ltd. lessened its holdings in shares of Medtronic PLC (NYSE:MDT) by 20.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 46,603 shares of the medical technology company’s stock after selling 11,981 shares during the quarter. Phoenix Financial Ltd.’s holdings in Medtronic were worth $4,609,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Artisan Partners Limited Partnership grew its stake in shares of Medtronic by 2.6% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after purchasing an additional 31,314 shares during the period. SageView Advisory Group LLC grew its stake in shares of Medtronic by 164.8% in the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock valued at $2,305,000 after purchasing an additional 15,062 shares during the period. CSM Advisors LLC grew its stake in shares of Medtronic by 13.2% in the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock valued at $27,169,000 after purchasing an additional 33,167 shares during the period. UMB Bank n.a. grew its stake in shares of Medtronic by 65.8% in the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after purchasing an additional 54,898 shares during the period. Finally, Applied Finance Capital Management LLC bought a new stake in shares of Medtronic in the 3rd quarter valued at approximately $1,308,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus lowered their price objective on Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Monday, April 6th. CICC Research started coverage on Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating on the stock. UBS Group decreased their price target on Medtronic from $104.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 22nd. Barclays increased their price target on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Finally, Daiwa Securities Group decreased their price target on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Fifteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.80.

Medtronic Stock Down 1.1%

NYSE MDT opened at $76.12 on Friday. The firm has a market cap of $97.73 billion, a PE ratio of 21.20, a price-to-earnings-growth ratio of 1.83 and a beta of 0.62. Medtronic PLC has a one year low of $74.40 and a one year high of $106.33. The stock’s 50 day simple moving average is $84.76 and its 200 day simple moving average is $93.64. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts forecast that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).